Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TxCell names new CEO

This article was originally published in Scrip

Executive Summary

Biotechnology company TxCell, which develops personalized cell-based immunotherapies using for chronic inflammatory and autoimmune diseases, has named Damian Marron chief executive officer. Prior to joining the Valbonne, France-based firm, Mr Marron was CEO of clinical stage biotechnology company Cytheris. Furthermore, from 2008-2012 he was CEO of Trophos. Under his tenure, Trophos spearheaded a group of major EU funded consortia of leading global experts and specialists working on a range of orphan diseases. Mr Marron succeeds Francois Meyer who has now been appointed executive chair of the TxCell's board of directors.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts